Online citations, reference lists, and bibliographies.

Refining American Joint Committee On Cancer/Union For International Cancer Control TNM Stage And Prognostic Groups For Human Papillomavirus-related Oropharyngeal Carcinomas.

Shao Hui Huang, Wei Xu, John W. F. Waldron, Lillian L. Siu, Xiaowei Shen, Li Tong, Jolie Ringash, Andrew J S Bayley, John Kim, Andrew Hope, John B.C. Cho, Meredith Giuliani, Aaron R Hansen, Jonathan C. Irish, Ralph Gilbert, Patrick Gullane, Bayardo Perez-Ordoñez, Ilan Weinreb, Fei-fei Liu, Brian O’sullivan
Published 2015 · Medicine
Cite This
Download PDF
Analyze on Scholarcy
Share
PURPOSE To refine stage and prognostic group for human papillomavirus (HPV) -related nonmetastatic (M0) oropharyngeal cancer (OPC). METHODS All patients with nonmetastatic (M0) p16-confirmed OPC treated with radiotherapy with or without chemotherapy from 2000 to 2010 were included. Overall survival (OS) was compared among TNM stages for patients with HPV-related and HPV-unrelated OPC separately. For HPV-related OPC, recursive partitioning analysis (RPA) derived new RPA stages objectively. Cox regression was used to calculate adjusted hazard ratios (AHRs) to derive AHR stages. The performance of survival prediction of RPA stage and AHR stage was assessed against the current seventh edition TNM stages. Prognostic groups were derived by RPA, combining RPA stage and nonanatomic factors. RESULTS The cohort comprised 573 patients with HPV-related OPC and 237 patients with HPV-unrelated OPC, with a median follow-up of 5.1 years. Lower 5-year OS with higher TNM stage was evident for patients with HPV-unrelated OPC (stage I, II, III, and IV 5-year OS: 70%, 58%, 50%, and 30%, respectively; P = .004) but not for patients with HPV-related OPC (stage I, II, III, and IV 5-year OS: 88%, 78%, 71%, and 74%, respectively; P = .56). RPA divided HPV-related OPC into RPA-I (T1-3N0-2b), RPA-II (T1-3N2c), and RPA-III (T4 or N3; 5-year OS: 82%, 76%, and 54%, respectively; P < .001). AHR also yielded a valid classification, but RPA stage demonstrated better survival prediction. A further RPA (including RPA stage, age, and smoking pack-years [PYs]) derived the following four valid prognostic groups for survival: group I (T1-3N0-N2c_≤ 20 PY), group II (T1-3N0-N2c_> 20 PY), group III (T4 or N3_age ≤ 70), and group IVA (T4 or N3_age > 70; 5-year OS: 89%, 64%, 57%, and 40%, respectively; P < .001). CONCLUSION An RPA-based TNM stage grouping (stage I/II/III: T1-3N0-N2b/T1-3N2c/T4 or N3, with M1 as stage IV) is proposed for HPV-related OPC as a result of significantly improved survival prediction compared with the seventh edition TNM, and prognostication is further improved by an RPA-based prognostic grouping within the American Joint Committee on Cancer/Union for International Cancer Control TNM framework for HPV-related OPC.
This paper references
Clinical trials. Broadcast: RTOG 0522
Kina Ang (2007)
10.1200/JCO.2012.44.0164
Deintensification candidate subgroups in human papillomavirus-related oropharyngeal cancer according to minimal risk of distant metastasis.
B O'Sullivan (2013)
10.1007/978-3-642-82982-6
TNM Classification of Malignant Tumours
Leslie Sobin (1987)
10.1016/j.ijrobp.2010.08.031
Atypical clinical behavior of p16-confirmed HPV-related oropharyngeal squamous cell carcinoma treated with radical radiotherapy.
Shao Hui Huang (2012)
10.1002/jso.10114
The TNM system: our language for cancer care.
Frederick L Greene (2002)
10.1002/hed.23360
Comorbidity and prognosis in head and neck cancers: Differences by subsite, stage, and human papillomavirus status.
Steven Habbous (2014)
10.1002/1097-0142(20010915)92:6<1484::AID-CNCR1473>3.0.CO;2-W
A comparison of published head and neck stage groupings in carcinomas of the tonsillar region.
Patti A. Groome (2001)
Pharynx, AJCC Cancer Staging Manual (ed
S Edge (2010)
10.1002/hed.21997
Matted nodes: poor prognostic marker in oropharyngeal squamous cell carcinoma independent of HPV and EGFR status.
Matthew E Spector (2012)
10.1126/science.1208130
The Mutational Landscape of Head and Neck Squamous Cell Carcinoma
Nicolas Stransky (2011)
10.1093/annonc/mds205
Human papillomavirus modifies the prognostic significance of T stage and possibly N stage in tonsillar cancer.
Angela M. Hong (2013)
The impact of the addition of chemotherapy to radiotherapy for cancer of the oropharynx in 2003/4: A population-based study from the Province of Ontario Canada
SF Hall (2014)
10.1007/978-1-4757-3656-4
AJCC Cancer Staging Manual
Mahul B. Amin (2002)
International Union Against Cancer: TNM Classification of Malignant Tumours (ed
L Sobin (2010)
10.1016/j.otc.2013.04.011
Evaluation and staging of squamous cell carcinoma of the oral cavity and oropharynx: limitations despite technological breakthroughs.
Mark E Zafereo (2013)
10.1016/j.oraloncology.2012.07.015
Natural course of distant metastases following radiotherapy or chemoradiotherapy in HPV-related oropharyngeal cancer.
Shao Hui Huang (2013)
10.1200/JCO.2011.38.4099
Tobacco smoking and increased risk of death and progression for patients with p16-positive and p16-negative oropharyngeal cancer.
Maura L. Gillison (2012)
Survival outcomes by tumor human papillomavirus (HPV) status in stage III-IV oropharyngeal cancer (OPC) in RTOG 0129.
Maura L. Gillison (2009)
10.1016/j.ejca.2006.09.001
Identification of differentially expressed genes in HPV-positive and HPV-negative oropharyngeal squamous cell carcinomas.
Iván Sánchez Martínez (2007)
10.1002/hed.23438
Patterns of nodal metastasis and prognosis in human papillomavirus-positive oropharyngeal squamous cell carcinoma.
Matthew E Spector (2014)
10.1016/j.oraloncology.2014.02.001
Refining risk stratification for locoregional failure after chemoradiotherapy in human papillomavirus-associated oropharyngeal cancer.
Jeffrey M. Vainshtein (2014)
10.1016/j.radonc.2009.04.014
Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients.
Jean-Pierre Pignon (2009)
10.1016/J.YPED.2010.12.093
Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer
James A. Stockman (2012)
10.1007/978-1-4612-4380-9_41
Bootstrap Methods: Another Look at the Jackknife
Bradley Efron (1979)
10.1002/jso.21237
A worldwide approach to the TNM staging system: collaborative efforts of the AJCC and UICC.
Frederick L Greene (2009)
10.1038/ncomms5006
Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach
Hugo Jwl Aerts (2014)
10.1002/cncr.27727
An evolution in demographics, treatment, and outcomes of oropharyngeal cancer at a major cancer center: a staging system in need of repair.
Kristina R Dahlstrom (2013)
10.1002/hed.23697
Staging and treatment of oropharyngeal cancer in the human papillomavirus era.
Matthew Alex Ward (2015)
10.1038/nrc1739
Biomarkers in Cancer Staging, Prognosis and Treatment Selection
Joseph A Ludwig (2005)
10.1200/JCO.2009.23.1670
Comparative prognostic value of HPV16 E6 mRNA compared with in situ hybridization for human oropharyngeal squamous carcinoma.
Wei Shi (2009)
10.1016/j.radonc.2010.03.015
Point-of-care outcome assessment in the cancer clinic: audit of data quality.
Karen W Y Wong (2010)
10.1016/j.ijrobp.2013.08.049
Temporal nodal regression and regional control after primary radiation therapy for N2-N3 head-and-neck cancer stratified by HPV status.
Shao Hui Huang (2013)



This paper is referenced by
10.1016/j.ejon.2018.05.003
Considerations for a head and neck smoking cessation support programme; A qualitative study of the challenges in quitting smoking after treatment for head and neck cancer.
Ameera Abdelrahim (2018)
10.1016/j.ejrad.2018.08.009
Diagnostic value of diffusion-weighted imaging and 18F-FDG-PET/CT for the detection of unknown primary head and neck cancer in patients presenting with cervical metastasis.
Daniel P Noij (2018)
10.1001/jamaoto.2019.0820
Development and Assessment of a Novel Composite Pathologic Risk Stratification for Surgically Resected Human Papillomavirus-Associated Oropharyngeal Cancer.
John D Cramer (2019)
10.1016/j.soncn.2019.08.003
Caring for Patients Treated With Checkpoint Inhibitors for the Treatment of Metastatic Merkel Cell Carcinoma.
Krista M. Rubin (2019)
10.12968/denu.2019.46.8.722
Head and Neck cancer part 1: diagnosis and classification
Oliver Jones (2019)
10.1002/hed.25749
American Joint Committee on Cancer eighth edition human papilloma virus positive oropharyngeal cancer staging system: Discordance between clinical and pathological staging systems.
Scott Hall (2019)
10.1016/j.semradonc.2017.08.007
The Current State of Biological and Clinical Implications of Human Papillomavirus-Related Oropharyngeal Cancer.
Shao Hui Huang (2018)
10.18632/oncotarget.15582
DEK associates with tumor stage and outcome in HPV16 positive oropharyngeal squamous cell carcinoma
Eric A. Smith (2017)
10.1007/s11864-017-0484-y
Overview of the 8th Edition TNM Classification for Head and Neck Cancer
Shao Hui Huang (2017)
10.1016/j.clon.2019.05.023
Advancing Care for Head and Neck Cancers in a Multidisciplinary Tumour Board in the East.
V H-F Lee (2019)
10.1002/cncr.32501
Stage I HPV-positive oropharyngeal cancer: Should all patients receive similar treatments?
Emi J. Yoshida (2019)
10.1016/j.oraloncology.2015.10.016
Understanding the impact of survival and human papillomavirus tumor status on timing of recurrence in oropharyngeal squamous cell carcinoma.
Theresa Guo (2016)
10.4137/CIN.S39364
Recursive Partitioning Method on Competing Risk Outcomes
Wei Xu (2016)
10.1007/s00106-017-0391-3
Die 8. Ausgabe der TNM‑Klassifikation
J. Doescher (2017)
Carcinoma pavimento-celular oral em jovens : a propósito de um caso clínico
Ana Cristina Antunes Vitorino (2017)
10.1016/j.oraloncology.2018.12.014
Refining the tumor-node-metastasis staging system for individualized treatment of differentiated thyroid carcinoma.
Young Nam Kim (2019)
10.1158/1940-6207.CAPR-15-0299
Serum Antibodies to HPV16 Early Proteins Warrant Investigation as Potential Biomarkers for Risk Stratification and Recurrence of HPV-Associated Oropharyngeal Cancer
Carole Fakhry (2015)
10.1016/j.anl.2017.07.010
The applicability of new TNM classification for humanpapilloma virus-related oropharyngeal cancer in the 8th edition of the AJCC/UICC TNM staging system in Japan: A single-centre study.
Daisuke Sano (2018)
10.1007/s00405-020-05991-z
‘Good cancer gone bad’: a narrative review of HPV oropharyngeal cancer and potential poor outcomes
Oludare Alabi (2020)
10.1002/lary.28665
Prognostic Significance of Lymph Node Status in p16+ Oropharyngeal Cancer After Surgical Treatment.
Young Min Park (2020)
10.1007/s10637-016-0367-2
Phase I trial of dacomitinib, a pan-human epidermal growth factor receptor (HER) inhibitor, with concurrent radiotherapy and cisplatin in patients with locoregionally advanced squamous cell carcinoma of the head and neck (XDC-001)
Amy Prawira (2016)
10.1200/JCO.2016.66.6081
Human Papillomavirus and Oropharyngeal Cancer Stage.
Maura L. Gillison (2016)
10.1002/hed.24515
Cigarette use, comorbidities, and prognosis in a prospective head and neck squamous cell carcinoma population.
Lisa A. Peterson (2016)
10.3174/ajnr.A5407
CT Texture Analysis Potentially Predicts Local Failure in Head and Neck Squamous Cell Carcinoma Treated with Chemoradiotherapy
Hirofumi Kuno (2017)
10.1007/s00106-018-0499-0
Staging von Oropharynxkarzinomen
Abbey Beltz (2018)
10.1155/2018/9594568
Association of p16 as Prognostic Factors for Oropharyngeal Cancer: Evaluation of p16 in 1470 Patients for a 16 Year Study in Northeast China
Hong-Xue Meng (2018)
10.1002/hed.24964
Predictors of contralateral‐bilateral nodal disease in oropharyngeal cancer: A National Cancer Data Base Study
Masanari G Kato (2018)
10.1002/hed.25523
Smoking and papillomavirus DNA in patients with p16‐positive N3 oropharyngeal squamous cell carcinoma
Philippe Gorphe (2019)
10.1002/cncr.31741
Proposed modifications and incorporation of plasma Epstein‐Barr virus DNA improve the TNM staging system for Epstein‐Barr virus‐related nasopharyngeal carcinoma
Rui Guo (2019)
10.1093/annonc/mdx304
Human papillomavirus-related oropharyngeal cancer
Miren Taberna (2017)
CLINICOPATHOLOGIC FACTORS FOR DISEASE-FREE SURVIVAL IN EARLY STAGE ORAL SQUAMOUS CELL CARCINOMA
Yingci Liu (2018)
10.18632/oncotarget.15107
Phase III randomized trial of preoperative concurrent chemoradiotherapy versus preoperative radiotherapy for patients with locally advanced head and neck squamous cell carcinoma
Junlin Yi (2017)
See more
Semantic Scholar Logo Some data provided by SemanticScholar